IP Library Granted Patent US 9,493,788
Granted Patent B2
US 9,493,788 · App. 14/598,462 · Granted Nov 15, 2016

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Inventors: Guangping Gao (Westborough, MA); James M. Wilson (Glen Mills, PA); Mauricio R. Alvira (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania
C12N15/86A61K35/761A61K38/177A61K38/45A61K38/4846C07K14/005C07K14/705C07K14/755C12N7/00C12N9/1018C12N9/644A61K48/00C12N2750/14122C12N2750/14143C12N2750/14152C12N2830/008C12N2830/48C12N2830/85C12Y201/03003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,493,788
App. No.
14/598,462
Granted
Nov 15, 2016
Kind
B2
Abstract

Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.

Claims (22)

1. An adeno-associated virus (AAV)8 viral vector comprising an AAV8 capsid having packaged therein a heterologous gene operably linked to regulatory sequences which direct its expression, wherein the heterologous gene encodes ornithine transcarbamylase (OTC), wherein the AAV8 capsid comprises a vp3 capsid protein having the sequence of aa 204 to 738 of SEQ ID NO: 2, or a sequence which is at least 95% identical to said sequence of aa 204 to 738 of SEQ ID NO: 2.

2. The vector according to claim 1 , wherein said OTC is human OTC.

3. The vector according to claim 1 , further comprising one or more AAV inverted terminal repeat (ITR) sequence from an AAV heterologous to AAV8.

4. The vector according to claim 3 , wherein the one or more AAV ITR is from AAV2.

5. A composition comprising the vector according to claim 1 and a pharmaceutically acceptable carrier.

6. A host cell containing the vector according to claim 1 in culture.

7. A method for treating OTC deficiency, said method comprising the step of contacting a cell with a vector according to claim 1 , wherein said vector directs expression of OTC.

8. The method according to claim 7 , wherein said vector is delivered via intravenous administration.

9. A composition comprising the vector according to claim 1 and a preservative or chemical stabilizer.

10. The vector according to claim 1 , wherein said vp3 capsid protein has a sequence which is at least 95% identical to the sequence of aa 204 to 738 of SEQ ID NO: 2.

11. The vector according to claim 10 , wherein said vp3 capsid protein has a sequence at least 99% identical to the sequence of aa 204 to 738 of SEQ ID NO: 2.

12. The vector according to claim 10 , wherein said vp3 capsid protein has the sequence of aa 204 to 738 of SEQ ID NO: 2.

13. The vector according to claim 1 , wherein said AAV8 capsid further comprises a vp1 capsid protein having a sequence which is at least 95% identical to the sequence of aa 1 to 738 of SEQ ID NO: 2.

14. The vector according to claim 13 , wherein said vp1 capsid protein has an amino acid sequence at least 99% identical to the sequence of aa 1 to 738 of SEQ ID NO: 2.

15. The vector according to claim 13 , wherein said vp1 capsid protein has the sequence of aa 1 to 738 of SEQ ID NO: 2.

16. The vector according to claim 1 , wherein said AAV8 capsid further comprises a vp2 capsid protein having a sequence which is at least 95% identical to the sequence of aa 138 to 738 of SEQ ID NO: 2.

17. The vector according to claim 16 , wherein said vp2 capsid protein has an amino acid sequence at least 99% identical to the sequence of aa 138 to 738 of SEQ ID NO: 2.

18. The vector according to claim 16 , wherein said vp2 capsid protein has the sequence of aa 138 to 738 of SEQ ID NO: 2.

19. A method of delivering a heterologous gene encoding ornithine transcarbamylase (OTC) to a cell, said method comprising contacting said cell with the vector according to claim 1 .

20. The method according to claim 19 , comprising delivering said vector to a hepatocyte.

21. A composition comprising at least an adeno-associated virus (AAV) vector and a physiologically compatible carrier, the AAV vector comprising an AAV capsid comprising at least an AAV8 vp3 capsid protein having a sequence comprising amino acids 204 to 738 of SEQ ID NO: 2 or an amino acid sequence at least 95% identical thereto, said capsid having packaged therein a heterologous gene operably linked to regulatory sequences which direct its expression, wherein the heterologous gene encodes ornithine transcarbamylase (OTC).

22. A composition comprising at least an adeno-associated virus (AAV) vector and a physiologically compatible carrier, the AAV vector comprising an AAV capsid comprising at least an AAV8 vp1 capsid protein having a sequence comprising amino acids 1 to 738 of SEQ ID NO: 2 or an amino acid sequence at least 95% identical thereto, said capsid having packaged therein a heterologous gene operably linked to regulatory sequences which direct its expression, wherein the heterologous gene encodes ornithine transcarbamylase (OTC).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2016
From: GAO, GUANGPING; WILSON, JAMES M.; ALVIRA, MAURICIO R.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 040275/0033 →
Continuity (8)
Division 11981022 · Oct 31, 2007
Continuation 11899500 · Sep 6, 2007
Continuation 10423704 · Apr 25, 2003
Continuation In Part PCTUS0233630 · Nov 12, 2002
Provisional Application 60386122 · Jun 5, 2002
Provisional Application 60377133 · May 1, 2002
Provisional Application 60341151 · Dec 17, 2001
Related Publication 20150139953A1 · May 21, 2015